Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma.
Fiche publication
Date publication
avril 2021
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Mme TRUNTZER Caroline
Tous les auteurs :
Lecuelle J, Aarnink A, Tharin Z, Truntzer C, Ghiringhelli F
Lien Pubmed
Résumé
The first line treatment of advanced pancreatic ductal adenocarcinoma cancer (PDAC) comprises a FOLFIRINOX regimen for most patients with good performance status. However, no biomarker to predict efficacy is currently available. We investigated whether exome sequencing could be used to predict progression-free and overall survival in patients undergoing FOLFIRINOX for PDAC.
Mots clés
FOLFIRINOX exome sequencing, PDAC, prognostic biomarkers
Référence
Cancers (Basel). 2021 Apr 13;13(8):